Human Osteopontin, N-terminal Monoclonal Antibody

Added to your cart

Human Osteopontin, N-terminal Monoclonal Antibody

Cart subtotal: £0.00

View cart (0) Checkout

#SKU MAB196P

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

Human Osteopontin (OPN) is a negatively charged hydrophilic protein of 314 amino acids and is subject to significant post translational modifications (PTM) including phosphorylation and glycosylation. Due to its acidic nature and PTMs, OPN runs anomalously by SDS-PAGE. Although its mass is 35kD, apparent molecular weights may range up to 75kD. In addition, OPN is subject to proteolytic modification into smaller molecular weight fragments.
MAB196P

More information

Attributes

Description

  • Abbreviations
  • OPN
  • Reference Texts
  • Alicia Plumer, Hongyi Duan, Sripriya Subramaniam, F. Lee Lucas, Susan Meisfeldt, Ah-Kau Ng, Lucy Liaw. Development of Fragment Specific Osteopontin Antibodies and ELISA for Quantification in Human Metastatic Breast Cancer. BMC Cancer 2008, 8:38.
  • Storage
  • Store at -20°C to -80°C, avoid repeat freeze- thaw
  • Manufacturer Country
  • USA
  • Buffer
  • 0.15M PBS
  • Disease Area
  • Cancer & Tumour
  • Purity/grade
  • determined by size-exclusion chromatography
  • Applications
  • ELISA, WB
  • Clone Number
  • 2H9
  • Immunogen / Epitope
  • Recombinant full-length human Osteopontin

Technical Documents

Certificates Of Analysis (31.1KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox